SSR-180711
SSR-180711 has been in phase II clinical trials by Sanofi for the treatment of schizophrenia and Alzheimer's disease. However, there is no development report for this study.
General Information
Update Date：2016-01-06
- Drug Name：
- SSR-180711
- Research Code：
- SSR-180711; SSR-180711A; SSR-180711C
- Trade Name：
- MOA：
- Alpha7 nicotinic acetylcholine receptor agonist
- Indication：
- Schizophrenia; Alzheimer's disease (AD)
- Status：
- Phase II (Pending)
- Company：
- Sanofi (Originator)
- Sales：
- ATC Code：
Chemical Structure
Update Date：2016-01-06
|
Molecular Weight | 361.66 | ||||||||||||
| Formula | C14H17BrN2O2 • HCl | |||||||||||||
| CAS No. |
298198-52-4 (SSR-180711A Free); 446031-79-4 (SSR-180711A); |
|||||||||||||
| Chemical Name | 1,4-Diazabicyclo[3.2.2]nonane-4-carboxylic acid, 4-bromophenyl ester, hydrochloride (1:1) | |||||||||||||
| SSR-180711A Free （Free Acid/Base）Parameters： | ||||||||||||||
|
||||||||||||||
| *：Calculated by ACD/Labs software V11.02. | ||||||||||||||